2014/12/19¬ü°êFDA§åã¨È°ö¤½¥q(AbbVie)ªºHCVÂû§À°s½Æ¤èÃÄVIEKIRA PAK™¤W¥«¡A¥Î©óªvÀø²Ä1«¬ºC©ÊC«¬¨xª¢¡F³¡¤À¯f±w»Ý¦±ß¨ÖªARibavirin¡A©Ò¥H¤@¤Ñ»ÝªA4©Î6¿õÃĤY¡A¤ñ¤@¤Ñ¤@ÁûHARVONIn³Â·Ð¤@¨Ç¡C¦b¥]¬A³¡¤ÀÃøªv¯f±wªºÁ{§É¸ÕÅ礤¡A12©PÀøµ{ªºVIEKIRA PAK¹ï²Ä1«¬ºC©ÊC«¬¨xª¢¦³91〜100%ªv¡²v¡A¨ÃÀòã¨Ï¥Î©ó¦X¨Ö¦³·R´þ¯f¡B¨xµw¤Æ¡B©Î´¿±µ¨ü¨xŦ²¾´Óªº¯f±w¡C
12©PÀøµ{ªºVIEKIRA PAK©w»ù88,319¬ü¤¸¡A¤ñHARVONI«K©y12%¡CµM¦Ó¨È°ö¤½¥qÅãµM§ó¼Ö·Nµ¹¤j«È¤á§éÅý¡A¦]¬°´N¦b¨â¤Ñ«á¡A¨C¦~¸g¤â9¤d¸U¬ü°ê¤H14»õ±i³B¤èºà¡B¥þ¬ü³Ì¤jªºÃĪ«¨Ñµ¹ºÞ²z¤½¥q§Ö±¶ÃĤè«Å¥¬¡A¦Û2015/01/01°_¡A¹ï²Ä1«¬ºC©ÊC«¬¨xª¢«È¤á¤£µ¹¥I¦N§Q¼wªºÃÄ«~¡A¨Ã¥B¤£¯f±¡´£¨ÑVIEKIRA PAKµ¹©Ò¦³²Ä1«¬C¨x«È¤á[9]¡C¥Ñ©óVIEKIRA PAK¥uã³\¨Ï¥Î©ó²Ä1«¬ºC©ÊC«¬¨xª¢¡A¥«³õ¦ôp¦N§Q¼wªº¥«¥e²v»P¦¬¯q¨Ã¤£·|¦]¦¹¤j´T¤U¶^¡F¦ý¥i¥H¹w´ÁSOVALDI»PVIEKIRA PAK¦b2015¦~¥þ²y¦U¦a¤´¦³¿E¯Pªº¥«³õª§¹Ü¾Ô¡C
Merck¡¦s chronic hepatitis C development program continues to focus on the goal of advancing a short-duration treatment regimen that offers high virologic cure rates across all viral genotypes. The strong results observed in this study support the further investigation of the novel triple-combination regimen of grazoprevir, MK-3682 and MK-8408 in patients with chronic hepatitis C.ALSO READ: 7 BioHealth Movers That Cannot Be Ignored
¡]¥»¤åª©ÅvÂk¹Dã´µ¤½¥q©Ò¦³¡A¥¼¸g³\¥i¤£±o½Ķ©ÎÂà¸ü¡C¡^
0
»sÃÄ°Ó¦N§Q¼w Gilead Sciences (GILD-US) ¥h¦~¥X»ù 119 »õ¬ü¤¸¨ÖÁʲüÄõ¥Íª«»sÃĤ½¥q³Í¯S Kite Pharma (KITE-US) ¨Ó±j¤Æ¨ä¦~ÁÚªº±M§Q²Õ¦X¤ÎÀù¯gÃĪ«¡C ²{¬°¤l¤½¥qªº³Í¯S¶g¥| (22 ¤é) «Å§G¯{ 30 »õ¬ü¤¸Àò±o Sangamo ¥Í§Þ¤½¥q (SGMO-US) ¾N«ü®Ö»Ä酶 (Zinc-finger nucleases, ZFN) ªº¿W®a¨Ï¥ÎÅv¡A¥i¥Î ZFN ¥¥x¶}µoÓ¤H¤Æªº CAR-T Àøµ{¡A¤]¨ô«©ó³o¤è±ªº»â¥ý¦a¦ì¡C ¦X¬ù±ø´Úµ²ºc¬°²{ª÷ 1.5 »õ¬ü¤¸¡A¤Î 30 »õ¬ü¤¸ªº¶}µo¸g¶O¡C¦N§Q¼w¶g¥| (22 ¤é) ªÑ»ù¤U¶^ 1.60% ¨Ó¨ì 79.40 ¬ü¤¸¡CSangamo ªÑ»ù«h¤Wº¦ 14.41% ¨Ó¨ì 25.40 ¬ü¤¸¡C CAR-T (Chimeric Antigen Receptor T Cells) Àøªk¥«³õ¬Û·íÄvª§¡A²{¥H³Í¯S¤Î¿ÕµØ Novartis (NVS-US) ³B©ó»â¥ýªº¦a¦ì¡C ¾Ú¤F¸Ñ¡ASangamo µ¹¤F³Í¯S»s³y¦ÛÅé²¾´Ó¤Î²§Åé²¾´Óªº¤ÏÀù²ÓMÀøªk¡C°£¦¹¤§¥~¡A³Í¯S¤]¥iÁקK¥t¥~¬ã¨s CAR-T Àøªkªº¿ÕµØ»P Juno Àò¨ú ZFN ªº¨Ï¥ÎÅv¡A¤@¥Û¤G³¾¡C¦P®É¡A³o¶µ¥æ©ö¤£¦ýµ¹¤F Sangamo ¤j¶qªº¸êª÷°µ³Ý®§¡A¤]¥i¨Ï¥«³õ§ó¦h®É¶¡Æ[¹î ZFN »P²{¦b¸ûÉqªº CRISPR °ò¦]§ï³y§Þ³N¡C ¦N§Q¼w´£¹D¡A¨Ï¥ÎÓ¤H¤Æ CAR-T ±NµL»Ý¯f±w»PÃĪ«°µ¡u¾AÀ³¡v¡A¤j¤jªºÁYµuª`®gÃĪ«ªº®É¨°¡C¦¹¥~¡A½÷·ç Pfizer (PFE-US) ¤ä´©ªº Cellectis¡A¤]¦P¼Ë¨Ï¥Î¨ä TALEN ¥¥x°µÓ¤H¤Æ CAR-T¡C¿ÕµØ¤Î Juno «h¬O¨Ï¥Î CRISPR/Cas9 ªº¤èªk»s³yÓ¤H¤Æ CAR-T¡C
Sangamo ªÑ»ù¤é½uÁͶչÏ
Åwªï¥úÁ{ ¤Úµá¯S¯Z ¬x·ç®õ (Michael On) (http://mikeon88.freebbs.tw/) | Powered by Discuz! 5.0.0 |